Aquestive Therapeutics (AQST) Change in Receivables (2017 - 2026)
Aquestive Therapeutics (AQST) posted quarterly Change in Receivables of -$10.9 million for Q1 2026, down 448.23% year-over-year from $3.1 million in Q1 2025, and down 282.85% quarter-over-quarter from $6.0 million in Q4 2025.
Aquestive Therapeutics (AQST) Change in Receivables (2017 - 2026) Analysis & Trends
Aquestive Therapeutics' Change in Receivables history runs 10 years deep, the most recent figure standing at -$10.9 million for Q1 2026.
- In Q1 2026, Change in Receivables fell 448.23% year-over-year to -$10.9 million; the TTM figure through Mar 2026 stood at -$3.7 million (down 267.42% YoY), while the FY2025 annual figure was $10.4 million, up 1048.08% from the prior year.
- Change in Receivables for Q1 2026 stood at -$10.9 million, down from $6.0 million in the prior quarter.
- The five-year high for Change in Receivables was $7.7 million in Q1 2022, with the low at -$10.9 million in Q1 2026.
- The 5-year median for Change in Receivables is -$104000.0 (2023), against an average of -$346882.4.
- The sharpest annual moves came in 2024 and 2025: Change in Receivables slumped 2132.69% in 2024, then jumped 2228.57% in 2025.
- Aquestive Therapeutics' Change in Receivables stood at -$6.1 million in 2022, then surged by 98.29% to -$104000.0 in 2023, then plunged by 2132.69% to -$2.3 million in 2024, then surged by 356.63% to $6.0 million in 2025, then slumped by 282.85% to -$10.9 million in 2026.
- Business Quant data shows AQST's Change in Receivables at -$10.9 million in Q1 2026, $6.0 million in Q4 2025, and -$63000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 91.00 Mn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 66.00 Mn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | -445.26 Mn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | -1.70 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 126.50 Mn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 84.30 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Aquestive Therapeutics | 560.60 Mn | 560.60 Mn | 9.80 Mn | 2.46 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.46 Mn |
| Jun 30, 2026 | 2.46 Mn |
| Mar 31, 2026 | -10.90 Mn |
| Mar 31, 2026 | -10.90 Mn |
| Dec 31, 2025 | 5.96 Mn |
| Dec 31, 2025 | 5.96 Mn |
| Sep 30, 2025 | -63,000.00 |
| Sep 30, 2025 | -63,000.00 |
| Jun 30, 2025 | 1.35 Mn |
| Jun 30, 2025 | 1.35 Mn |
| Mar 31, 2025 | 3.13 Mn |
| Mar 31, 2025 | 3.13 Mn |
| Dec 31, 2024 | -2.32 Mn |
| Dec 31, 2024 | -2.32 Mn |
| Sep 30, 2024 | 3.71 Mn |
| Sep 30, 2024 | 3.71 Mn |
| Jun 30, 2024 | -2.34 Mn |
| Jun 30, 2024 | -2.34 Mn |
| Mar 31, 2024 | -147,000.00 |
| Mar 31, 2024 | -147,000.00 |